Clinical trial
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without…
NCT00083031 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00083031 |
|---|---|
| Title | Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer |
| Official title | Metronomic Chemotherapy With Bevacizumab for Advanced Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, cyclophosphamide, methotrexate |
| Enrollment | 57 |
| Start date | Jul 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2009 |
| First posted | May 17, 2004 |
| Last update posted | May 21, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: